D. Dudley

发表

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

A Versatile Copper-Catalyzed Coupling Reaction of Pyridin-2(1H)-ones with Aryl Halides.

A. Casimiro-Garcia, K. J. Filipski, D. Dudley, 2006 .

Progress in the discovery of Factor Xa inhibitors

A. Casimiro-Garcia, C. Bigge, K. J. Filipski, 2006 .

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.

Steve Price, E. Bradley, BinQing Wei, 2013, Journal of medicinal chemistry.

Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.

M. Belvin, E. Bradley, M. Ultsch, 2013 .

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Brian J. Smith, J. Baell, G. Nikolakopoulos, 2014, ACS medicinal chemistry letters.

Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.

D. R. Holland, L. Chi, T. Mertz, 2000, Journal of medicinal chemistry.

The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2.

M. Adler, M. Whitlow, E. Zhang, 2005, Bioorganic & medicinal chemistry letters.

The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.

M. Adler, M. Whitlow, E. Zhang, 2006, Bioorganic & Medicinal Chemistry Letters.

Structure‐based Drug Design of Pyrrolidine‐1, 2‐dicarboxamides as a Novel Series of Orally Bioavailable Factor Xa Inhibitors

E. Zhang, Tom McClanahan, A. Casimiro-Garcia, 2007, Chemical biology & drug design.

The Discovery of (2R,4R)‐N‐(4‐chlorophenyl)‐N‐ (2‐fluoro‐4‐(2‐oxopyridin‐1(2H)‐yl)phenyl)‐4‐methoxypyrrolidine‐1,2‐dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor

L. Chi, E. Zhang, Tom McClanahan, 2007, Chemical biology & drug design.

Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.

D. R. Holland, L. Chi, T. Mertz, 2004, Journal of medicinal chemistry.

Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.

Kevin J Filipski, Igor Mochalkin, V. Sahasrabudhe, 2009, Bioorganic & medicinal chemistry.

Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

J. Ohren, A. Geyer, A. Casimiro-Garcia, 2011, Journal of medicinal chemistry.

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.

J. Blake, Jianping Yin, Weiru Wang, 2014, Bioorganic & medicinal chemistry letters.

Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.

Steve Price, M. Belvin, BinQing Wei, 2013, Bioorganic & medicinal chemistry letters.